Tacforius

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
10-01-2023
产品特点 产品特点 (SPC)
10-01-2023
公众评估报告 公众评估报告 (PAR)
26-01-2018

有效成分:

tacrolimus monohydrate

可用日期:

Teva B.V.

ATC代码:

L04AD02

INN(国际名称):

tacrolimus

治疗组:

Immunosuppressants

治疗领域:

Liver Transplantation; Kidney Transplantation

疗效迹象:

Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

產品總結:

Revision: 7

授权状态:

Authorised

授权日期:

2017-12-08

资料单张

                                51
B. PACKAGE LEAFLET
52
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TACFORIUS 0.5 MG PROLONGED-RELEASE HARD CAPSULES
TACFORIUS 1 MG PROLONGED-RELEASE HARD CAPSULES
TACFORIUS 3 MG PROLONGED-RELEASE HARD CAPSULES
TACFORIUS 5 MG PROLONGED-RELEASE HARD CAPSULES
tacrolimus
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs and illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Tacforius is and what it is used for
2.
What you need to know before you take Tacforius
3.
How to take Tacforius
4.
Possible side effects
5.
How to store Tacforius
6.
Contents of the pack and other information
1.
WHAT TACFORIUS IS AND WHAT IT IS USED FOR
Tacforius contains the active substance tacrolimus. It is an
immunosuppressant. Following your organ
transplant (liver, kidney), your body’s immune system will try to
reject the new organ. Tacforius is
used to control your body’s immune response, enabling your body to
accept the transplanted organ.
You may also be given Tacforius for an ongoing rejection of your
transplanted liver, kidney, heart or
other organ when any previous treatment you were taking was unable to
control this immune response
after your transplantation.
Tacforius is used in adults.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE TACFORIUS
_ _
DO NOT TAKE TACFORIUS_ _
-
if you are allergic to tacrolimus or any of the other ingredients of
this medicine (listed in
section 6).
-
if you are allergic to sirolimus or to any macrolide-antibiotic (e.g.,
erythromycin,
clarithromycin, josamycin).
WARNINGS AND PRECAUTIONS
Tacrolimus immediate release capsules (e.g, Tacni) and 
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Tacforius 0.5 mg prolonged-release hard capsules
Tacforius 1 mg prolonged-release hard capsules
Tacforius 3 mg prolonged-release hard capsules
Tacforius 5 mg prolonged-release hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Tacforius 0.5 mg prolonged-release hard capsules
Each prolonged-release hard capsule contains 0.5 mg tacrolimus (as
monohydrate).
_Excipient with known effect _
Each capsule contains 53.725 mg lactose.
Tacforius 1 mg prolonged-release hard capsules
Each prolonged-release hard capsule contains 1 mg tacrolimus (as
monohydrate).
_Excipient with known effect _
Each capsule contains 107.45 mg lactose.
Tacforius 3 mg prolonged-release hard capsules
Each prolonged-release hard capsule contains 3 mg tacrolimus (as
monohydrate).
_Excipient with known effect _
Each capsule contains 322.35 mg lactose.
Tacforius 5 mg prolonged-release hard capsules
Each prolonged-release hard capsule contains 5 mg tacrolimus (as
monohydrate).
_Excipients with known effect _
Each capsule contains 537.25 mg lactose and 0.0154 mg ponceau 4R.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Prolonged-release hard capsule (prolonged-release capsule)
Tacforius 0.5 mg prolonged-release hard capsules
Gelatin capsules imprinted with “TR” on the light yellow capsule
cap and “0.5 mg” on the light orange
capsule body.
Tacforius 1 mg prolonged-release hard capsules
Gelatin capsules imprinted with “TR” on the white capsule cap and
“1 mg” on the light orange capsule
body.
3
Tacforius 3 mg prolonged-release hard capsules
Gelatin capsules imprinted with “TR” on the light orange capsule
cap and “3 mg” on the light orange
capsule body.
Tacforius 5 mg prolonged-release hard capsules
Gelatin capsules imprinted with “TR” on the greyish red capsule
cap and “5 mg” on the light orange
capsule body.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Prophylaxis of transplant rejection in adult kidney or
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 10-01-2023
产品特点 产品特点 保加利亚文 10-01-2023
公众评估报告 公众评估报告 保加利亚文 26-01-2018
资料单张 资料单张 西班牙文 10-01-2023
产品特点 产品特点 西班牙文 10-01-2023
公众评估报告 公众评估报告 西班牙文 26-01-2018
资料单张 资料单张 捷克文 10-01-2023
产品特点 产品特点 捷克文 10-01-2023
公众评估报告 公众评估报告 捷克文 26-01-2018
资料单张 资料单张 丹麦文 10-01-2023
产品特点 产品特点 丹麦文 10-01-2023
公众评估报告 公众评估报告 丹麦文 26-01-2018
资料单张 资料单张 德文 10-01-2023
产品特点 产品特点 德文 10-01-2023
公众评估报告 公众评估报告 德文 26-01-2018
资料单张 资料单张 爱沙尼亚文 10-01-2023
产品特点 产品特点 爱沙尼亚文 10-01-2023
公众评估报告 公众评估报告 爱沙尼亚文 26-01-2018
资料单张 资料单张 希腊文 10-01-2023
产品特点 产品特点 希腊文 10-01-2023
公众评估报告 公众评估报告 希腊文 26-01-2018
资料单张 资料单张 法文 10-01-2023
产品特点 产品特点 法文 10-01-2023
公众评估报告 公众评估报告 法文 26-01-2018
资料单张 资料单张 意大利文 10-01-2023
产品特点 产品特点 意大利文 10-01-2023
公众评估报告 公众评估报告 意大利文 26-01-2018
资料单张 资料单张 拉脱维亚文 10-01-2023
产品特点 产品特点 拉脱维亚文 10-01-2023
公众评估报告 公众评估报告 拉脱维亚文 26-01-2018
资料单张 资料单张 立陶宛文 10-01-2023
产品特点 产品特点 立陶宛文 10-01-2023
公众评估报告 公众评估报告 立陶宛文 26-01-2018
资料单张 资料单张 匈牙利文 10-01-2023
产品特点 产品特点 匈牙利文 10-01-2023
公众评估报告 公众评估报告 匈牙利文 26-01-2018
资料单张 资料单张 马耳他文 10-01-2023
产品特点 产品特点 马耳他文 10-01-2023
公众评估报告 公众评估报告 马耳他文 26-01-2018
资料单张 资料单张 荷兰文 10-01-2023
产品特点 产品特点 荷兰文 10-01-2023
公众评估报告 公众评估报告 荷兰文 26-01-2018
资料单张 资料单张 波兰文 10-01-2023
产品特点 产品特点 波兰文 10-01-2023
公众评估报告 公众评估报告 波兰文 26-01-2018
资料单张 资料单张 葡萄牙文 10-01-2023
产品特点 产品特点 葡萄牙文 10-01-2023
公众评估报告 公众评估报告 葡萄牙文 26-01-2018
资料单张 资料单张 罗马尼亚文 10-01-2023
产品特点 产品特点 罗马尼亚文 10-01-2023
公众评估报告 公众评估报告 罗马尼亚文 26-01-2018
资料单张 资料单张 斯洛伐克文 10-01-2023
产品特点 产品特点 斯洛伐克文 10-01-2023
公众评估报告 公众评估报告 斯洛伐克文 26-01-2018
资料单张 资料单张 斯洛文尼亚文 10-01-2023
产品特点 产品特点 斯洛文尼亚文 10-01-2023
公众评估报告 公众评估报告 斯洛文尼亚文 26-01-2018
资料单张 资料单张 芬兰文 10-01-2023
产品特点 产品特点 芬兰文 10-01-2023
公众评估报告 公众评估报告 芬兰文 26-01-2018
资料单张 资料单张 瑞典文 10-01-2023
产品特点 产品特点 瑞典文 10-01-2023
公众评估报告 公众评估报告 瑞典文 26-01-2018
资料单张 资料单张 挪威文 10-01-2023
产品特点 产品特点 挪威文 10-01-2023
资料单张 资料单张 冰岛文 10-01-2023
产品特点 产品特点 冰岛文 10-01-2023
资料单张 资料单张 克罗地亚文 10-01-2023
产品特点 产品特点 克罗地亚文 10-01-2023
公众评估报告 公众评估报告 克罗地亚文 26-01-2018

搜索与此产品相关的警报

查看文件历史